Executive Summary
- Nuclear medicine is experiencing remarkable commercial growth: rising capital investment and patent filings signal a shift from last-resort therapy to precision medicine that diagnoses and treats disease simultaneously, transforming it into a multi-billion-dollar therapeutic platform with applications beyond cancer.
- Biomarker diagnostics represent a convergence of clinical need, scientific pipeline, and advancing technology. Early detection dramatically improves survival rates, and the shift from symptomatic to pre-symptomatic detection suggests significant market expansion as well as meaningful patient impacts.
- Analysis of 350,000+ immuno-oncology publications from the CAS Content Collection identified 300+ emerging topics across eight oncology branches. As the field enters its next growth phase, diversification beyond first-generation checkpoint inhibitors—into ADCs, next-gen CAR-T, cancer vaccines, and advanced delivery platforms—will likely define the path forward.
- Spatial transcriptomics transforms tissue samples into spatially resolved molecular maps, enabling precision medicine that improves target selection, predicts responders, and explains treatment failures. Though early-stage, it has strong potential to address pharma's costliest R&D challenges.
Precision oncology continues to evolve rapidly as new technologies reshape how researchers understand, diagnose, and treat cancer. The following topics address specific areas of interest within personalized cancer care, and this page serves as a central hub that guides users into deeper resources and insights. The pace of innovation in cancer research is impressive. Look no further than the rise of precision oncology and immunotherapy to see how quickly the field is advancing.
One key to these breakthroughs? High-quality data about biomarkers and gene expression at the cellular level. These findings can inspire even more data-driven research as discoveries build upon each other. With a comprehensive view of the research landscape and interconnected data sources, it’s possible to see which concepts are growing quickly, where disciplines are interacting, and what the next breakthroughs are likely to be. At CAS, we have our finger on the pulse of these data-driven insights.
Theranostics: Cancer diagnosis meets targeted therapy
Radiopharmaceuticals used for PET or SPECT imaging can identify cancer cells and deliver targeted radiation therapy at the same time. This “see it and treat it” approach reduces off-target effects and improves patient outcomes: the exact goals of precision oncology.
White Paper
CAS Insights Spotlight
Understanding the research landscape with advanced technologies
Big data analysis also reveals which concepts are growing quickly but with fewer publications, versus well-established fields with high overall numbers but low growth. Using co-occurrence analysis, CAS Insights scientists can point to which areas are more likely to lead to new breakthroughs. We can also see how AI is already making a major impact on drug discovery as one example of how computer-aided drug design is revolutionizing oncology.
Biomarkers: Driving earlier detection and more effective treatments
Biomarkers are proteins, nucleic acids, and other small organic molecules that signal the presence of cancer. The recent 30% increase in biomarker-related publications shows how these discoveries are changing strategies for early detection and precision therapies.
Spatial transcriptomics: Mapping the tumor microenvironment
A major challenge in oncology is understanding tumor heterogeneity and the surrounding microenvironment. Spatial transcriptomics reveals gene expression within tissues, giving researchers more clues into disease progression for breast cancer, glioblastoma, oral squamous cell carcinoma, and more.
Big data and AI: Accelerating immuno-oncology decisions
The vast amount of cancer research calls for clinical informatics and advanced analytical tools. For example, in a CAS analysis, researchers used natural language processing (NLP) to identify over 300 emerging concepts across eight oncology-specific categories.
More on immuno-oncology
Co-occurring concepts reveal new research directions in immuno-oncology
Numerous emerging ideas in immuno-oncology are poised to revolutionize treatment options an patient outcomes. Our scientists used the CAS Content Collection to find connections between topics to direct future research efforts. They used NLP-based methodology to analyze relevant publications before developing CAS TrendScape Maps for greater examination. This identified the most promising areas where immuno-oncology innovation will occur.
The future of cancer treatment
Major challenges and opportunities exist across the entire cancer research and treatment landscape. Part of how we'll get there is through data-driven insights based on a comprehensive view of the available research. Faster cures and treatments, informed investments, and better outcomes for patients are the future of personalized cancer care.
Organizations facing data harmonization challenges, whether digitizing legacy records, normalizing compound libraries, or preparing datasets for AI modeling, can discuss custom data solutions designed around specific scientific domains and existing infrastructure. Research groups implementing AI strategies that are uncertain about data quality and governance can consult with CAS specialists who combine scientific expertise with data infrastructure experience to assess readiness and identify gaps in existing systems.
Accelerating precision oncology from the lab to the clinic requires tools that can process vast amounts of data and guide researchers to the most impactful findings. That's only possible with comprehensive data sets, expert data governance, and advanced technologies. With CAS as your partner, your organization can access the largest curated repository of scientific information along with advanced analytical capabilities.
